Alembic Pharmaceuticals Ratios

Alembic Pharmaceuticals Ltd Ratios

The Alembic Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Alembic Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Alembic Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Alembic Pharmaceuticals Ltd (NSE: APLLTD, BSE: 533573) is currently trading at ₹677.30, with a market capitalization of ₹133.08B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Alembic Pharmaceuticals Ltd remains a key stock for fundamental analysis using Alembic Pharmaceuticals Ltd Ratios.

Alembic Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Alembic Pharmaceuticals Ltd P/E ratio currently stands at 31.31, making it one of the most tracked metrics in Alembic Pharmaceuticals Ltd Ratios.

Historically, the Alembic Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 31.31
• 2023: 31.36
• 2022: 28.51
• 2021: 27.97
• 2020: 16.31

The decline in Alembic Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Alembic Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.52.

Historical P/B trend:

• 2024: 3.52
• 2023: 4.01
• 2022: 2.22
• 2021: 2.79

Alembic Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Alembic Pharmaceuticals Ltd P/S ratio currently stands at 2.79, an important part of Alembic Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 2.79
• 2023: 3.15
• 2022: 1.75
• 2021: 2.77

A stable or declining Alembic Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Alembic Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Alembic Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 1230.

Historical Alembic Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 1230
• 2023: 25.49
• 2022: 14.44
• 2021: 28.85
• 2020: 13.43

The rising Alembic Pharmaceuticals Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Alembic Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Alembic Pharmaceuticals Ltd EV currently stands at ₹194.32B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 194.32B
• 2023: 196.96B
• 2022: 103.88B
• 2021: 152.2B

Alembic Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Alembic Pharmaceuticals Ltd EV/EBITDA ratio is currently 21.49, a key metric in Alembic Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 21.49
• 2023: 23.21
• 2022: 15.65
• 2021: 17.73

Stable Alembic Pharmaceuticals Ltd EV/EBITDA indicates balanced valuation.

Alembic Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Alembic Pharmaceuticals Ltd D/E ratio is currently 0.24, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.24
• 2023: 0.11
• 2022: 0.16
• 2021: 0.14

Alembic Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Alembic Pharmaceuticals Ltd ROE currently stands at 11.66%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.66
• 2023: 13.38
• 2022: 7.12
• 2021: 10.17

Alembic Pharmaceuticals Ltd maintains stable profitability levels.

Alembic Pharmaceuticals Ltd Ratios Analysis Summary

The Alembic Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Alembic Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Alembic Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.